

Health Protection scorecard - February 2021

	Significantly worse than England
	Not significantly different to England
	Significantly better than England
	Significance not tested
-	No sub-regional data available
	Above national goal
	Close to national goal
	Below national goal

	Data updated since previous scorecard?	Indicator	Measure	Period	County Durham		North East	England	Recent trend
					No.	Measure			
Screening	N	2.19 - Cancer diagnosed at early stage (experimental statistics)	%	2017	1,171	49.3%	52.4%	52.2%	
	Y	C24a - Cancer screening coverage - breast cancer	%	2020	50,271	77.9%	76.3%	74.1%	
	Y	C24b - Cancer screening coverage - cervical cancer (25 - 49 years)	%	2020	62,719	76.9%	77.2%	70.2%	
	Y	C24c - Cancer screening coverage - cervical cancer (50 - 64 years)	%	2020	39,407	77.4%	76.5%	76.1%	
	Y	C24d - Cancer screening coverage - bowel cancer	%	2020	58,376	66.0%	65.1%	63.8%	
	Y	C24e - Abdominal Aortic Aneurysm Screening - Coverage	%	2019/20	2,616	80.4%	78.3%	76.1%	
	N	C25b – Diabetic eye screening - uptake (%)	%	2018/19	-	-	83.2%	82.6%	
	N	C24h - Infectious Diseases in Pregnancy Screening – HIV Coverage (%)	%	2018/19	-	-	99.7%	99.7%	
	N	C24i - Infectious Diseases in Pregnancy Screening – Syphilis Coverage (%)	%	2018/19	-	-	99.7%	99.7%	
	N	C24j - Infectious Diseases in Pregnancy Screening – Hepatitis B Coverage (%)	%	2018/19	-	-	99.7%	99.7%	
	N	C24k - Sickle Cell and Thalassaemia Screening – Coverage (%)	%	2018/19	-	-	99.7%	99.7%	
	N	C24l - Newborn Blood Spot Screening – Coverage (%)	%	2018/19	-	-	99.0%	97.8%	
	Y	C24m - Newborn Hearing Screening – Coverage (%)	%	2019/20	4,523	98.1%	98.4%	98.2%	
	N	C24n - Newborn and Infant Physical Examination Screening – Coverage (%)	%	2018/19	-	-	95.1%	96.4%	

	Data updated since previous scorecard?	Indicator	Measure	Period	County Durham		North East	England	Recent trend
					No.	Measure			
Imms and Vaccs		12 months							
	N	D03b - Population vaccination coverage - Hepatitis B (1 year old)	%	2019/20	-	100%	-	-	
	N	D03c - Population vaccination coverage - Dtap / IPV / Hib (1 year old)	%	2019/20	4,922	97.8%	96.0%	92.6%	
			<90% 90% to 95% ≥95%						
	N	3.03iv - Population vaccination coverage - MenC <i>**From 1st July 2016 the dose of MenC offered at 3 months is to be discontinued and so the 1 year evaluation 3.03iv indicator will become obsolete within the next two years (data for 2016/17 will be the last collection) **</i>	%	2015/16	5,399	98.7%	97.8%	*	
			<90% 90% to 95% ≥95%						
	N	D03f - Population vaccination coverage - PCV (1 year old)	%	2019/20	4,923	97.8%	96.4%	93.2%	
			<90% 90% to 95% ≥95%						
			24 months						
	N	D03g - Population vaccination coverage - Hepatitis B (2 years old)	%	2019/20	-	100%	-	-	
	N	D03h - Population vaccination coverage - Dtap / IPV / Hib (2 years old)	%	2019/20	5,047	98.0%	96.6%	93.8%	
			<90% 90% to 95% ≥95%						
	N	D03m - Population vaccination coverage - Hib / MenC booster (2 years old)	%	2018/19	4,993	96.9%	95.1%	90.5%	
			<90% 90% to 95% ≥95%						
	N	D03k - Population vaccination coverage - PCV booster (2 years old)	%	2019/20	5,001	97.1%	95.2%	90.4%	
			<90% 90% to 95% ≥95%						
	N	D03j - Population vaccination coverage - MMR for one dose (2 years old)	%	2019/20	4,987	96.8%	95.1%	90.6%	
			<90% 90% to 95% ≥95%						
			2-3 years						
	N	D03l - Population vaccination coverage - Flu (2-3 years old)	%	2019/20	5,250	49.2%	48.4	43.8%	
			<40% 40% to 65% >65%						
			5 years						
	N	D04b - Population vaccination coverage - MMR for one dose (5 years old)	%	2019/20	5,438	98.1%	96.8%	94.5%	
		<90% 90% to 95% ≥95%							
N	3.03vi - Population vaccination coverage - Hib / Men C booster (5 years old)	%	2017/18	5,768	97.2%	95.1%	92.4%		
		<90% 90% to 95% ≥95%							
N	D04c - Population vaccination coverage - MMR for two doses (5 years old)	%	2019/20	5,329	96.1%	92.0%	86.8%		
		<90% 90% to 95% ≥95%							
		Other Children and young people							
N	D04e - Population vaccination coverage - HPV vaccination coverage for one dose (females 12-13 years old)	%	2018/19	2,368	88.0%	86.3%	88.0%		
		<80% 80% to 90% ≥90%							
N	D04f - Population vaccination coverage - HPV vaccination coverage for two doses (females 13-14 years old)	%	2018/19	2,383	87.8%	84.8%	83.9%		
		<80% 80% to 90% >90%							
		Other							
N	Persons entering substance misuse treatment - Percentage of eligible persons completing a course of hepatitis B vacc		2016/17	32	3.6%	6.0%	8.1%		
N	D05 - Population vaccination coverage - Flu (at risk individuals)	%	2019/20	33,673	47.4%	46.9%	44.9%		
		<55% ≥55%							
N	D06a - Population vaccination coverage - Flu (aged 65+)	%	2019/20	79,686	72.1%	83.8%	72.4%		
		<75% ≥75%							
N	D06b - Population vaccination coverage - PPV (aged 65+)	%	2019/20	80,132	71.6%	70.9%	69.0%		
		<65% 65% to 75% ≥75%							
N	D06c - Population vaccination coverage - Shingles vaccination coverage (70 years old)	%	2017/18	3,513	47.6%	45.0%	44.4%	No trend	
		<50% 50% to 60% ≥60%							

	Data updated since previous scorecard?	Indicator	Measure	Period	County Durham		North East	England	Recent trend
					No.	Measure			
Sexual health	N	D02a - Chlamydia detection rate / 100,000 aged 15-24	R/100,000	2019	985	1505	1869	2043	
			<1,900 1,900 to 2,300 ≥2,300						
	N	D02b - All new STI diagnoses (exc Chlamydia aged <25) / 100,000	R/100,000	2019	1915	574	648	900	
	N	Gonorrhoea diagnosis rate per 100,000 population	R/100,000	2019	294	55	73	123	
N	Syphilis diagnoses rate per 100,000 population	R/100,000	2019	36	6.8	10.4	13.8		
N	D07 - HIV late diagnosis (%)	R/100,000	2016-18	20	33.3%	42.9	42.5		
									≥50% 25% to 50% <25%
Infectious diseases	N	Legionnaire's disease confirmed incidence rate / 100,000	R/100,000	2016	3	0.57	0.53	0.61	
	N	Typhoid and paratyphoid confirmed incidence rate / 100,000	R/100,000	2018	2	38.0%	0.15	0.61	
	Y	D08b - TB incidence (three year average)	R/100,000	2017-19	32	2	3.9	8.6	
	N	3.05i - Treatment completion for TB (%)*	%	2017	4	50	74.7	84.7	
	N	Measles (reported cases confirmed, Year to date)	R/100,000	Q2 2019	0	0	0.15	-	
	N	Measles new diagnosis rate	R/100,000	2018	1	0.2	0.5	1.7	
	N	<i>Mumps (confirmed cases, quarterly number and annualised rates)</i>	R/100,000	Q2 2019	14	10.4	1.3	-	
	N	<i>Whooping cough (confirmed cases, quarterly number and annualised rates)</i>	R/100,000	Q2 2019	6	4.55	3.31	-	
	N	<i>Rubella (confirmed cases, year to date)</i>	R/100,000	Q2 2019	0	0	0	-	No trend
	N	<i>Meningococcal Infection (confirmed cases, quarterly number and annualised rates)</i>	R/100,000	Q2 2019	1	0.76	1.2	-	
	N	<i>Scarlet Fever (all notifications)</i>	R/100,000	Q2 2019	20	15.2	27.2	-	
	N	<i>Haemophilus Influenzae Type B (HiB)</i>	R/100,000	Q2 2019	0	0	0	-	
	N	Non-typhoidal Salmonella (incidence)	R/100,000	2017	92	17.6	16.6	15.7	
	N	<i>Quarterly Salmonella Enteritidis (incidence)</i>	R/100,000	Q2 2019	5	3.8	3.2	-	
	N	<i>Quarterly Salmonella Typhimurium (incidence)</i>	R/100,000	Q2 2019	5	3.8	1.8	-	
	N	<i>Quarterly Salmonella other (incidence)</i>	R/100,000	Q2 2019	9	6.8	5.7	-	
	N	Campylobacter (incidence)	R/100,000	2017	689	132	123	97	
	N	<i>Quarterly Campylobacter (incidence)</i>	R/100,000	Q2 2019	168	127.5	126.7	-	
	N	Cryptosporidium (incidence)	R/100,000	2017	75	14.4	10.4	7.3	
	N	<i>Quarterly Cryptosporidium (incidence)</i>	R/100,000	Q2 2019	11	8.3	4.7	-	
	N	Giardia (incidence)	R/100,000	2017	35	6.7	11.9	8.5	
	N	<i>Quarterly Giardia (incidence)</i>	R/100,000	Q2 2019	10	7.6	8.6	-	
	N	STEC serogroup O157 (incidence)	R/100,000	2018	13	2.5	2	1	

	Data updated since previous scorecard?	Indicator	Measure	Period	North Durham CCG		North Durham recent trend	Durham Dales, Easington And Sedgefield CCG		STP	England	DDES recent trend
					Count	Value		Count	Value			
Health Care Acquired Infection	Y	All C. difficile rates by CCG and financial year	R/100,000	2018/19	48	19.3		60	21.9	28.8	22	
	Y	All MRSA bacteraemia rates by CCG and financial year	R/100,000	2018/19	3	1.2		2	0.7	1	1.4	
	N	CCG-assigned MRSA rates by CCG and financial year	R/100,000	2016/17	1	0.4		3	1.1	0.57	0.4	
	Y	All MSSA bacteraemia rates by CCG and financial year	R/100,000	2018/19	50	20.1		59	21.5	27.7	21.8	
	N	Trust-assigned MRSA counts by CCG and financial year	R/100,000	2016/17	3	3		4	4	-	315	
	N	Third party-assigned MRSA counts by CCG and financial year	R/100,000	2016/17	0	0		0	0	-	276	
	Y	All E. coli bacteraemia rates by CCG and financial year	R/100,000	2018/19	180	72.3		301	109.6	104.7	77.7	
	N	Counts and 12-month rolling rates of C. difficile infection, by CCG and month	R/100,000	Sep-18	8	20.2		8	22.2	28.7	23.8	
	N	Counts and 12-month rolling rates of all MRSA bacteraemia cases, by CCG and month	R/100,000	Sep-18	0	2		0	0.7	1.2	1.5	
	N	Counts and 12-month rolling rates of MSSA bacteraemia cases, by CCG and month	R/100,000	Sep-18	4	17.4		6	20.4	27.9	21.7	
	N	Counts and 12-month rolling rates of E. coli bacteraemia by CCG and month	R/100,000	Sep-18	17	71.1		22	91	101	76.2	
	N	Counts and 12-month rolling rates of hospital-onset E. coli bacteraemia, by CCG and month	R/100,000	Sep-18	8	17.1		3	10.1	20.1	13.8	
	N	Counts and 12-month rolling rates of community-onset E. coli bacteraemia, by CCG and month	R/100,000	Sep-18	14	61		17	73.9	81	62.4	